Diagnostics for Brain Health
Gryphon Bio is a clinical stage company created to harness our co-founders' discovery, over more than 20 years of -omic research, of unexpected waves of 1000s of brain molecules in the blood. The levels of brain-specific molecules in the blood change over time, like waves in the ocean, and can serve as targets for novel blood tests of brain health.
Mission: To develop and market novel blood tests for brain health.
Vision: To pioneer novel blood tests to improve the lives of patients.
We closely engage with our courageous patients to assess needs and to improve our blood tests for early disease detection and monitoring of brain health. Results from blood tests will be used by care providers to inform on key decisions such as recovery, hospitalization, and return-to-work/play/duty.
Our novel blood tests for brain health can also enrich and track patients responding to various drugs. This de-risks and accelerates our partners' drug discovery and development workflows, thereby increasing the likelihood of achieving successful outcomes in clinical trials and regulatory approvals.
OUR COURAGEOUS PATIENTS
Brain health is affected by a number of CNS diseases, including:
Traumatic brain injury (TBI)
Alzheimer's disease (AD)
Neonatal Encephalopathy (NE)
Post-traumatic epilepsy (PTE)
Alexander's disease (AxD)
Alzheimer's disease related dementias (ADRD)
Multiple sclerosis (MS)
Brain metastatic breast cancer (bmBC)
Chronic traumatic encephalopathy (CTE)
Frontotemporal degeneration (FTD)
Spinal cord injury (SCI)
Non-Dilutive Funding (Grant Awards & Contracts)
Total Cash Raised
OUR COURAGEOUS TEAM
We are a proven, cohesive, interdisciplinary and internationally recognized team with deep experience in blood test development.
WILL HASKINS, PHD
CEO & Co-Founder
Dr. Haskins previously led teams for R&D of gene therapies, therapeutic antibody, and antibody-drug conjugates from Research through Phase I/II/III clinical trials for small and large biotechnology companies, including Genentech. Dr. Haskins is well-respected for developing and applying out-of-the-box solutions to challenging problems. He is highly experienced with analytical and bioanalytical chemistry, proteomics, bioinformatics, CNS biomarkers, and large molecule drug development (OCREVUS®, KADCYLA®, POLIVY®, etc.). He has authored or co-authored more than 73 peer-reviewed publications and numerous patents, and he is the Principal Investigator for several federal grant awards. Lastly, Dr. Haskins completed postdoctoral fellowships at the McKnight Brain Institute and Lawrence Livermore National Laboratories after earning his PhD in Bioanalytical Chemistry from the University of Florida in 2003.
KEVIN WANG, PHD
Co-Founder & Chair of Scientific Advisory Board
Dr. Wang is a Professor & Vice-Chair for Research, Department of Neurobiology, Director, Center for Neurotrauma, Multiomics & Biomarkers (CNMB) at Morehouse School of Medicine Depart of Neurobiology and the Neuroscience Institute, (9/2022 – pres). He was formerly Director of Program for Neurotrauma Neuroproteomics & Biomarkers Research (NNBR), Assoc. Professor of Emergency Medicine, Psychiatry and Neuroscience, University of Florida McKnight Brain Institute and Research Neuroscientist at the Brain Rehabilitation Research Center (BRRC) at Malcom Randall VA Medical Center (Gainesville, FL). He is internationally recognized for his original contributions to the fields of CNS disorders-linked proteolytic enzymes, neuroproteomics and disease biomarker discovery in TBI and brain injury research. He is the past president of the National Neurotrauma Society (2012) and Councilor (2013 – 2016). He also has expertise in translational research into clinical studies, including clinical neuro-disease studies. His recent research directions include subacute and chronic TBI biomarker candidate identification/validation and developing amplification-based biomarker detection platforms of novel biomarkers. Two TBI protein biomarkers (UCH-L1 and GFAP) that Dr. Wang discovered, developed assays and conducted clinical validation on have now obtained FDA clearance as first-in-class in vitro diagnostics for CT-detectable lesions in TBI patients. Dr. Wang is also Biomarker Co-Lead for the NIH-funded/TRACK-TBI and DOD-funded/TBI Endpoint Development projects, as well as Biomarker Co-lead of the European commission-funded CENTER-TBI study. Dr. Wang is Co-Chair of the Biomarker Workgroup of the International Traumatic Brain Injury Research Initiative (InTBIR). Through the TRACK-TBI/TED initiatives, he helped the team obtain a Letter of Support from the FDA to encourage the use of biofluid-based markers (GFAP and UCH-L1) as drug development tools in TBI therapeutic intervention clinical trials (Jan, 2018).
LISA H. MERCK, MD MPH MA FACEP
Dr. Merck has worked in the execution of acute care clinical trials for over 15 years. She has studies of traumatic brain injury, COVID response, stroke, status epilepticus, and cardiac arrest. Dr. Merck also leads initiatives to train undergraduate, graduate, and post-doctoral students in clinical and translational research.
SWETHA MAHESULA, MS
A scientific professional with proven experience in leading, designing, and executing preclinical studies for research and development of novel biologics and biomarkers.
ANTHONY DELIZZA, MS
Senior Consultant, Diagnostics
Tony has 30 years’ experience in biosampling and diagnostic product development, including his leadership role in CLIA laboratory testing services and as a product executive for one of the leading U.S. brands for glucose monitoring.
DEVIN JACKSON, PHD
Senior Research Scientist
A scientific professional with proven experience in leading, designing, and executing clinical studies for research and development of novel blood tests.
KRISTY RADEKER, MSM
Associate Director, Clinical Operations & Finance
A professional with over 17 years of experience in research administration, clinical operations, financial management, and strategic decision making.
If you want to learn more about our amazing team members, get in touch.
OUR LATEST NEWS
Check our news section on a regular basis to always stay in the loop.
13. GRYPHON BIO RECEIVES NEW DOD GRANT AWARD TO ADVANCE CRITICAL RESEARCH IN POST-TRAUMATIC EPILEPSY
October 29, 2023
South San Francisco, CA – Sunday, July 1, 2023– Gryphon Bio, Inc. and Citizens United for Research in Epilepsy (CURE), together with Cambridge University, Morehouse School of Medicine, and Mario Negri Institute for Pharmacological Research IRCCS (IRFMN), were awarded more than $1.2M in Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP)-funding for its Epilepsy Research Program (ERP)-sponsored research multi-year grant award entitled “Temporal Dynamics of Astrocytic Activation and Function in Post-Traumatic Epilepsy (PTE) Genesis and Progression”. Background: Post-traumatic epilepsy (PTE) is when someone experiences recurring and unprovoked seizures after sustaining a traumatic brain injury (TBI). PTE is a common and serious complication of TBI. There are no FDA-approved medicines for prevention or treatment of PTE beyond current antiepileptic drugs, and there are no blood tests based on biomarkers for PTE. The disease course from TBI to PTE is not well understood, which further hampers the development of novel biomarkers and therapeutic targets. This project aims to identify specific changes in astrocytes, which are special star-shaped cells in the central nervous system, and how they contribute to the transition from TBI to PTE. Based on evidence we gathered in our previously funded DoD grant, which revealed molecules associated with astrocytes are activated in mice with PTE, compared to mice without PTE, we believe that astrocyte signatures have a key role in the progression from TBI to PTE. We think that by clarifying how these signatures impact TBI/PTE, we can identify novel PTE-associated molecules for future blood tests and therapeutics for PTE. We will do this by integrating various neuroimaging and large-scale molecular analyses to characterize the temporal dynamics of astrocytic signatures both before and after PTE starts, in a mouse model and in patient samples. According to Gryphon Bio CEO and Principal Investigator Will Haskins, “This grant award provides essential funding for improving our understanding of the molecular mechanisms of astrocytes in TBI and PTE patients.”